View in EDS

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.

Saved in:
Bibliographic Details
Title: A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
Authors: Camidge DR; University of Colorado Cancer Center, Aurora, Colorado., Barlesi F; Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale Centre National de la Recherche Scientifique, Aix Marseille University, Marseille, France.; Gustave Roussy, Villejuif, France., Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California., Morgensztern D; Washington University School of Medicine, St. Louis, Missouri., Heist R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Vokes E; University of Chicago Medicine, Chicago, Illinois., Angevin E; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Hong DS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rybkin II; Henry Ford Health System, Detroit, Michigan., Barve M; Mary Crowley Cancer Research Center, Dallas, Texas., Bauer TM; Sarah Cannon Research Institute, Nashville, Tennessee., Delmonte A; Medical Oncology Division, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Dunbar M; AbbVie Inc., North Chicago, Illinois., Motwani M; AbbVie Inc., North Chicago, Illinois., Parikh A; AbbVie Inc., Redwood City, California., Noon E; AbbVie Inc., North Chicago, Illinois., Wu J; AbbVie Inc., North Chicago, Illinois., Blot V; AbbVie Inc., Redwood City, California., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, California.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2021 Dec 04; Vol. 3 (1), pp. 100262. Date of Electronic Publication: 2021 Dec 04 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35005654
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Camidge+DR%22">Camidge DR</searchLink>; University of Colorado Cancer Center, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Barlesi+F%22">Barlesi F</searchLink>; Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale Centre National de la Recherche Scientifique, Aix Marseille University, Marseille, France.; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Goldman+JW%22">Goldman JW</searchLink>; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Morgensztern+D%22">Morgensztern D</searchLink>; Washington University School of Medicine, St. Louis, Missouri.<br /><searchLink fieldCode="AU" term="%22Heist+R%22">Heist R</searchLink>; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Vokes+E%22">Vokes E</searchLink>; University of Chicago Medicine, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Angevin+E%22">Angevin E</searchLink>; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Rybkin+II%22">Rybkin II</searchLink>; Henry Ford Health System, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Barve+M%22">Barve M</searchLink>; Mary Crowley Cancer Research Center, Dallas, Texas.<br /><searchLink fieldCode="AU" term="%22Bauer+TM%22">Bauer TM</searchLink>; Sarah Cannon Research Institute, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Delmonte+A%22">Delmonte A</searchLink>; Medical Oncology Division, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Dunbar+M%22">Dunbar M</searchLink>; AbbVie Inc., North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Motwani+M%22">Motwani M</searchLink>; AbbVie Inc., North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Parikh+A%22">Parikh A</searchLink>; AbbVie Inc., Redwood City, California.<br /><searchLink fieldCode="AU" term="%22Noon+E%22">Noon E</searchLink>; AbbVie Inc., North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; AbbVie Inc., North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Blot+V%22">Blot V</searchLink>; AbbVie Inc., Redwood City, California.<br /><searchLink fieldCode="AU" term="%22Kelly+K%22">Kelly K</searchLink>; University of California Davis Comprehensive Cancer Center, Sacramento, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2021 Dec 04; Vol. 3 (1), pp. 100262. <i>Date of Electronic Publication: </i>2021 Dec 04 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35005654
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2021.100262
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100262
    Titles:
      – TitleFull: A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Camidge DR
      – PersonEntity:
          Name:
            NameFull: Barlesi F
      – PersonEntity:
          Name:
            NameFull: Goldman JW
      – PersonEntity:
          Name:
            NameFull: Morgensztern D
      – PersonEntity:
          Name:
            NameFull: Heist R
      – PersonEntity:
          Name:
            NameFull: Vokes E
      – PersonEntity:
          Name:
            NameFull: Angevin E
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Rybkin II
      – PersonEntity:
          Name:
            NameFull: Barve M
      – PersonEntity:
          Name:
            NameFull: Bauer TM
      – PersonEntity:
          Name:
            NameFull: Delmonte A
      – PersonEntity:
          Name:
            NameFull: Dunbar M
      – PersonEntity:
          Name:
            NameFull: Motwani M
      – PersonEntity:
          Name:
            NameFull: Parikh A
      – PersonEntity:
          Name:
            NameFull: Noon E
      – PersonEntity:
          Name:
            NameFull: Wu J
      – PersonEntity:
          Name:
            NameFull: Blot V
      – PersonEntity:
          Name:
            NameFull: Kelly K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 12
              Text: 2021 Dec 04
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1